scholarly journals A systematic review on mutation markers for bladder cancer diagnosis in urine

2020 ◽  
Vol 127 (1) ◽  
pp. 12-27
Author(s):  
Anouk E. Hentschel ◽  
Emma E. Toom ◽  
André N. Vis ◽  
Johannes C.F. Ket ◽  
Judith Bosschieter ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Cancer Diagnosis

scholarly journals The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence

2017 ◽  
Vol 11 (4) ◽  
pp. 453-461 ◽  
Author(s):  
Amanda J. Edmondson ◽  
Jacqueline C. Birtwistle ◽  
James W.F. Catto ◽  
Maureen Twiddy
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Cancer Diagnosis ◽  
Qualitative Evidence ◽  
Patients Experience

Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis

2019 ◽  
Vol 37 (10) ◽  
pp. 2001-2007 ◽  
Author(s):  
Herney Andrés García-Perdomo ◽  
Juan Pablo Usubillaga-Velasquez ◽  
James Alejandro Zapata-Copete ◽  
Leonardo Oliveira Reis
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Cancer Diagnosis ◽  
Meta Analysis

Low vitamin D is associated with increased bladder cancer risk; a systematic review and evidence of a potential mechanism

2016 ◽  
Author(s):  
Rosemary Bland ◽  
Corina Chivu ◽  
Kieran Jefferson ◽  
Donald MacDonald ◽  
Gulnaz Iqbal ◽  
...  
Keyword(s):  
Systematic Review ◽  
Vitamin D ◽  
Bladder Cancer ◽  
Cancer Risk ◽  
Potential Mechanism ◽  
Bladder Cancer Risk

Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis

2021 ◽  
Vol 60 (5) ◽  
pp. 635-644
Author(s):  
Jeremy Tey ◽  
Francis Ho ◽  
Wee Yao Koh ◽  
David Chia ◽  
Kiat Huat Ooi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Meta Analysis ◽  
Palliative Radiotherapy

scholarly journals New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review

2020 ◽  
Author(s):  
Ara Jo ◽  
Lisa Scarton ◽  
LaToya J. O'Neal ◽  
Samantha Larson ◽  
Nancy Schafer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cancer Diagnosis ◽  
After Cancer ◽  
New Onset

scholarly journals Decision support tools to improve cancer diagnostic decision making in primary care: a systematic review

2019 ◽  
Vol 69 (689) ◽  
pp. e809-e818 ◽  
Author(s):  
Sophie Chima ◽  
Jeanette C Reece ◽  
Kristi Milley ◽  
Shakira Milton ◽  
Jennifer G McIntosh ◽  
...  
Keyword(s):  
Systematic Review ◽  
Primary Care ◽  
Decision Making ◽  
Decision Support ◽  
Cost Effectiveness ◽  
Cancer Diagnosis ◽  
Decision Support Tools ◽  
Diagnostic Decision ◽  
Support Tools ◽  
Diagnostic Decision Making

BackgroundThe diagnosis of cancer in primary care is complex and challenging. Electronic clinical decision support tools (eCDSTs) have been proposed as an approach to improve GP decision making, but no systematic review has examined their role in cancer diagnosis.AimTo investigate whether eCDSTs improve diagnostic decision making for cancer in primary care and to determine which elements influence successful implementation.Design and settingA systematic review of relevant studies conducted worldwide and published in English between 1 January 1998 and 31 December 2018.MethodPreferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched, and a consultation of reference lists and citation tracking was carried out. Exclusion criteria included the absence of eCDSTs used in asymptomatic populations, and studies that did not involve support delivered to the GP. The most relevant Joanna Briggs Institute Critical Appraisal Checklists were applied according to study design of the included paper.ResultsOf the nine studies included, three showed improvements in decision making for cancer diagnosis, three demonstrated positive effects on secondary clinical or health service outcomes such as prescribing, quality of referrals, or cost-effectiveness, and one study found a reduction in time to cancer diagnosis. Barriers to implementation included trust, the compatibility of eCDST recommendations with the GP’s role as a gatekeeper, and impact on workflow.ConclusioneCDSTs have the capacity to improve decision making for a cancer diagnosis, but the optimal mode of delivery remains unclear. Although such tools could assist GPs in the future, further well-designed trials of all eCDSTs are needed to determine their cost-effectiveness and the most appropriate implementation methods.

scholarly journals Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 351
Author(s):  
Massimiliano Creta ◽  
Giuseppe Celentano ◽  
Luigi Napolitano ◽  
Roberto La Rocca ◽  
Marco Capece ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bladder Cancer ◽  
Relative Risk ◽  
Clinical Studies ◽  
Clinical Evidence ◽  
Meta Analysis ◽  
Bladder Tumour ◽  
Signalling Pathways ◽  
Reductase Inhibitors ◽  
The Impact

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.

Efficacy of hypermethylated DNA biomarkers in saliva and oral swabs for oral cancer diagnosis: Systematic review and meta‐analysis

Oral Diseases ◽  
2021 ◽  
Author(s):  
John Adeoye ◽  
Azeez Arisekola Alade ◽  
Wang‐yong Zhu ◽  
Weilan Wang ◽  
Siu‐Wai Choi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Oral Cancer ◽  
Cancer Diagnosis ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document